ASLAN Pharmaceuticals Limited (ASLN)
Company Description
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients.
The company's clinical portfolio comprises ASLAN004, a monoclonal antibody that targets the IL-13 receptor a1 subunit which is being developed for the treatment of atopic dermatitis and other immunology indications; and ASLAN003, a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune diseases.
It has a joint venture with JAGUAHR Therapeutics Pte. Ltd. and Bukwang Pharmaceutical Co., Ltd. to develop immuno-oncology therapeutics for markets targeting the AhR pathway.
Its partners include Almirall, Array BioPharma, and CSL Limited. The company was founded in 2010 and is headquartered in Singapore.
Country | Singapore |
Founded | 2010 |
IPO Date | May 4, 2018 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 34 |
CEO | Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. |
Contact Details
Address: 83 Clemenceau Avenue, #12-03 Ue Square Singapore, U0 239920 Singapore | |
Phone | 65 6222 4235 |
Website | aslanpharma.com |
Stock Details
Ticker Symbol | ASLN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001722926 |
CUSIP Number | 04522R101 |
ISIN Number | US04522R2004 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. | Founder, Chief Executive Officer and Executive Director |
Kiran Kumar Asarpota | Chief Operating Officer and Head of Finance |
Ben Goodger | General Counsel |
Stephen Doyle | Chief Business Officer |
Dr. Alexandre Kaoukhov M.D. | Chief Medical Officer |
Charlie Hsu | Investor Relations Director |
Chi-Chin Wang | IR and Corporate Development Director |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Mar 28, 2024 | D | Notice of Exempt Offering of Securities |
Mar 25, 2024 | F-3 | Filing |
Mar 21, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Mar 19, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
Mar 14, 2024 | 424B5 | Filing |
Mar 13, 2024 | 6-K | Report of foreign issuer |
Mar 11, 2024 | 6-K | Report of foreign issuer |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Feb 6, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |